Lung Cancer

FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients
Updated Lung Cancer Guidelines Acknowledge Former Smoker's Risk Of Lung Cancer Never Disappears — 5M More Americans Eligible For Screening
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Updated Lung Cancer Guidelines Acknowledge Former Smoker's Risk Of Lung Cancer Never Disappears — 5M More Americans Eligible For Screening
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact

Lung Cancer Recent News

Oncocyte Shares Fall On Posting Wider Than Expected Q2 Loss
BeyondSpring Stock Is Up More than 300%: What You Need To Know?
BeyondSpring Inc (NASDAQ: BYSI) is trading over 300% up during premarket in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in combination with docetaxel.
Lixte Biotechnology Shares Are Trading Higher On Encouraging Preclinical LB-100 Data In Lung Cancer
Iovance Biotherapeutics' TIL Therapy Achieves ORR Of 21.4% In Pre-Treated Lung Cancer Patients
Mirati's KRAS Inhibitor Receives FDA Breakthrough Tag For Lung Cancer Harboring KRAS Mutation
Sanofi - Regeneron's Immunotherapy Scores European Approval For Skin And Lung Cancer Settings
AstraZeneca Unveils 5-Year Survival Data for Imfinzi in Lung Cancer Patients
Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China
Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer
AstraZeneca's Tagrisso Wins European Approval In Early Lung Cancer
JNJ's Rybrevant Scores FDA Approval In Lung Cancer Patients With EGFR Exon 20 Mutation
Advaxis' ADXS-503 Shows Durable Benefit Beyond One Year in Lung Cancer Patients Progressing on Merck's Keytruda
Heat Biologics' Lead Candidate Shows Overall Survival Benefit In Lung Cancer Study
AstraZeneca's Tagrisso Scores Approval In China For Early Lung Cancer
Pulmatrix Stock Is Trading Lower After JNJ's Lung Cancer Initiative Terminates PUR1800 Licensing Pact
FDA Ok's Roche's Companion Diagnostic For Pfizer's Lorbrena In Lung Cancer
Sorrento Developed Socazolimab Enters Late-Stage Lung Cancer Study In China
China's regulatory authorities have signed off on Lee's
G1 Therapeutics' Trilaciclib Wins FDA Nod For Mitigating Chemo Effects In Lung Cancer Patients
AstraZeneca Lung Cancer Drug Gets EU Approval
AstraZeneca Plc’s (NYSE: AZN) developmental drug – Imfinizi, has been approved by the European Commission after the Phase 3 clinical trial yielded positive results.
Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Sponsored
Penny Stock Rips 260% Higher On Fast Track Designation For Experimental Lung Cancer Gene Therapy
AstraZeneca's Triple Combo Lung Cancer Therapy Aces Late-Stage Trial
The Bull Thesis For Merck Is Evaporating